It has reported the most powerful association between PD-L1 and decreased survival in TNBC (Soliman et al., 2014), and more importantly, and the PD1 and PD-L1 has been shown to be a proactive therapy target for invasive breast cancer (Bertucci et al., 2016). Here, PDCD1 is linked to invasive breast carcinoma.